Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.
作者： Ellen Weisberg , James D. Griffin
关键词:
摘要: Abstract The tyrosine kinase inhibitor imatinib (ST1571, Glivec) blocks the activity of BCR/ABL oncogene and induces hematologic remissions in majority patients with chronic myeloid leukemia (CML). Glivec is an aminopyrimidine derivative that interacts ATP-binding site within domain ABL several other kinases, including c-KIT, PDGFβ receptor, ARG. The compound currently phase III clinical trials. Although CML have been found to develop drug resistance only rarely so far, more advanced phases frequently. available information on will be reviewed.
elsevier.com
sci-hub.se 参考文章(29)
Matulonis U, Griffin Jd, Salgia R, Okuda K, Druker B, Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Experimental Hematology. ,vol. 21, pp. 1460- 1466 ,(1993)
Dwayne L. Barber, Jacqueline M. Mason, Toru Fukazawa, Kris A. Reedquist, Brian J. Druker, Hamid Band, Alan D. D'Andrea, Erythropoietin and Interleukin-3 Activate Tyrosine Phosphorylation of CBL and Association With CRK Adaptor Proteins Blood. ,vol. 89, pp. 3166- 3174 ,(1997) , 10.1182/BLOOD.V89.9.3166
Philipp le Coutre, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino, Carlo Gambacorti-Passerini, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. ,vol. 95, pp. 1758- 1766 ,(2000) , 10.1182/BLOOD.V95.5.1758.005A41_1758_1766
François Xavier Mahon, Michael W. N. Deininger, Beate Schultheis, Jérome Chabrol, Josy Reiffers, John M. Goldman, Junia V. Melo, Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood. ,vol. 96, pp. 1070- 1079 ,(2000) , 10.1182/BLOOD.V96.3.1070
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
Eizo Kakishita, Yuko Usuki, Shuki Mizutani, Masumi Komai, Junji Nishimura, Hideo Kaneko, Hiroshi Wada, Domenico Delia, Akihisa Kanamaru, Shunji Sakamoto, Masatoshi Kohsaki, Establishment and Molecular Characterization of a Novel Leukemic Cell Line with Philadelphia Chromosome Expressing p230 BCR/ABL Fusion Protein Cancer Research. ,vol. 55, pp. 3192- 3196 ,(1995)
Amie S Corbin, Elisabeth Buchdunger, Furet Pascal, Brian J Druker, None, Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. Journal of Biological Chemistry. ,vol. 277, pp. 32214- 32219 ,(2002) , 10.1074/JBC.M111525200
T. Skorski, M. Nieborowska-Skorska, P. Wlodarski, D. Perrotti, R. Martinez, M. A. Wasik, B. Calabretta, Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase Proceedings of the National Academy of Sciences of the United States of America. ,vol. 93, pp. 13137- 13142 ,(1996) , 10.1073/PNAS.93.23.13137
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561
Keiko Okuda, Ellen Weisberg, D. Gary Gilliland, James D. Griffin, ARG tyrosine kinase activity is inhibited by STI571. Blood. ,vol. 97, pp. 2440- 2448 ,(2001) , 10.1182/BLOOD.V97.8.2440